Jean‐Luc Canon
Grand Charleroi Hospital(BE)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study(2010)1,795 cited
- → Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer(2015)160 cited
- → Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation(2016)122 cited
- → Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer(2018)101 cited
- → Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?(2007)74 cited
- → A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial(2021)54 cited
- → Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies(2003)47 cited
- → A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer(2016)44 cited
- → A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors(2016)30 cited
- → An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer(2012)22 cited